Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
TUG-891 is an agonist of free fatty acid receptor 4 (FFAR4/GPR120; EC50s = 0.0436 and 0.0169 µM for the human and mouse receptors, respectively).1 It is selective for FFAR4 over FFAR1/GPR40 (EC50 = 64.5 µM for the human receptor) and is inactive against FFAR2/GPR43 and FFAR3/GPR41. TUG-891 (1 µM) inhibits lysophosphatidic acid- or EGF-induced proliferation and migration of DU145 and PC3 prostate cancer cells.2 It stimulates glucagon-like peptide 1 (GLP-1) release in STC-1 enteroendrocrine cells and glucose uptake in 3T3-L1 adipocytes, as well as inhibits LPS-induced TNF-α release in RAW 264.7 macrophages when used at a concentration of 10 µM.3 TUG-891 (20 mg/kg) reduces sleep fragmentation-induced increases in food consumption and epididymal fat mass in mice.4
WARNING This product is not for human or veterinary use.
1. Discovery of a potent and selective GPR120 agonist. J. Med. Chem. 55(9), 4511-4515 (2012).
2. Omega-
3. The pharmacology of TUG-
4. Treatment with TUG891, a free fatty acid receptor 4 agonist, restores adipose tissue metabolic dysfunction following chronic sleep fragmentation in mice. Int. J. Obes. (Lond.) 40(7), 1143-1149 (2016).